Standard BioTools Inc. Common Stock
Here’s whether Standard BioTools Inc. Common Stock (LAB) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-8.04% over 10 days); RSI 18 — oversold; weak 1-year return of -44.2%; 3-month momentum negative (-35.0%). Currently 61.1% off its 52-week high. Score: -7/7.
LAB is trading below its 200-day MA ($1.09) — a key warning sign the longer-term trend is under pressure. An RSI of 17.9 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -44.3% compares to +20.5% for SPY (trailed the market by 64.7%). The current 61.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.